Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 241

Special Issue Editor


E-Mail Website
Guest Editor
Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland
Interests: pancreatic cancer; colorectal cancer; hepatocellular cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pancreatic cancer therapy is progressing slowly but step by step. Surgery remains a potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC) without metastases, and en bloc resection with adequate surgical margins is associated with long-term survival. Venous invasion does not preclude patients from surgery because combined venous resection and reconstitution can be safely performed. Resection and reconstitution of the affected arteries without a significant increase in mortality have been recently reported. Despite advanced surgery, most patients will develop metastatic disease, and there is therefore a great deal of debate about how to improve patient survival by using neoadjuvant or adjuvant chemotherapy with or without radiation therapy. Optimal supportive management, in particular nutritional treatment and care for PDAC patients in order to achieve a good quality of life, currently plays an increasingly important role. In the age of molecularly targeted drugs and immunotherapy, researchers take great efforts to find the best targeted therapy based on the genomics and proteomics of PDAC. Using our many years of experience in the treatment of patients with PDAC and taking into account the latest scientific achievements, this Special Issue will discuss recent developments in understanding genomic characteristics, early-detection approaches, and innovations in the treatment of resectable, borderline resectable, locally advanced, and metastatic PDAC, as well as recent developments in the application of therapeutics targeting new targets in pancreatic carcinoma.

Prof. Dr. Andrzej Deptała
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • pancreatic ductal adenocarcinoma
  • genetic changes
  • genomics
  • surgical resection
  • radiotherapy
  • radiochemotherapy
  • chemotherapy
  • targeted therapy
  • immunotherapy
  • resectable tumor
  • borderline resectable tumor
  • metastatic disease
  • nutritional treatment
  • quality of life

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 998 KiB  
Review
Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer—Where Are We Now?
by Marta Fudalej, Kamila Krupa, Anna Badowska-Kozakiewicz and Andrzej Deptała
Cancers 2025, 17(9), 1484; https://doi.org/10.3390/cancers17091484 - 28 Apr 2025
Viewed by 197
Abstract
Pancreatic cancer (PC) is one of the most commonly diagnosed and deadliest neoplasms in the modern world. Over the past few years, the incidence of PC has risen with only a slight improvement in overall survival. Moreover, the improvement in survival is primarily [...] Read more.
Pancreatic cancer (PC) is one of the most commonly diagnosed and deadliest neoplasms in the modern world. Over the past few years, the incidence of PC has risen with only a slight improvement in overall survival. Moreover, the improvement in survival is primarily driven by diagnoses in the localized stage of the disease, rather than by new treatment methods. The inflammatory process is a key mediator of PC development, yet PC is also one of the most immune-resistant tumors. Patients rarely benefit from monotherapy with immune checkpoint inhibitors; nevertheless, the latest biological findings on the complexity of the pancreatic tumor microenvironment might be translated into designing new clinical studies that combine various approaches to overcome single-agent immunotherapy resistance. On the other hand, focusing on inflammation may lead to the development of new inflammation-based prognostic markers for patients. This review aims to describe the current state of knowledge regarding the complex relationships between systemic and local inflammation, immune response, immunosuppression, and therapeutic options in PC. Full article
Show Figures

Figure 1

Back to TopTop